Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2004-7-12
pubmed:abstractText
Granulomatous inflammation is a typical feature of Takayasu arteritis (TA), and tumor necrosis factor (TNF) is important in the formation of granulomas. In this study, we assessed therapy with anti-TNF agents in patients with TA that was not controlled by glucocorticoid therapy or other immunosuppressants.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0004-3591
pubmed:author
pubmed:issnType
Print
pubmed:volume
50
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2296-304
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:15248230-Adolescent, pubmed-meshheading:15248230-Adult, pubmed-meshheading:15248230-Anti-Inflammatory Agents, pubmed-meshheading:15248230-Anti-Inflammatory Agents, Non-Steroidal, pubmed-meshheading:15248230-Antibodies, Monoclonal, pubmed-meshheading:15248230-Dose-Response Relationship, Drug, pubmed-meshheading:15248230-Drug Administration Schedule, pubmed-meshheading:15248230-Female, pubmed-meshheading:15248230-Glucocorticoids, pubmed-meshheading:15248230-Humans, pubmed-meshheading:15248230-Immunoglobulin G, pubmed-meshheading:15248230-Male, pubmed-meshheading:15248230-Middle Aged, pubmed-meshheading:15248230-Pilot Projects, pubmed-meshheading:15248230-Prednisone, pubmed-meshheading:15248230-Receptors, Tumor Necrosis Factor, pubmed-meshheading:15248230-Recurrence, pubmed-meshheading:15248230-Remission Induction, pubmed-meshheading:15248230-Takayasu Arteritis
pubmed:year
2004
pubmed:articleTitle
Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis.
pubmed:affiliation
Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. hoffmag@ccf.org
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Case Reports, Controlled Clinical Trial, Research Support, Non-U.S. Gov't, Multicenter Study